Centralization and Oncologic Outcomes in Ovarian Cancer
Recruiting
Observational Study
Epithelial Ovarian Cancer
Ovarian Neoplasms
Advanced Ovarian Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Female
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Azienda USL Reggio Emilia - IRCCS · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia.
The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithel…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female patients aged between 18 and 99 years
* Histological and/or cytological diagnosis of epithelial ovarian cancer
* Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
* Patients treated between January 1, 2018, and December 31,…
Contacts
Vincenzo Dario Mandato, MD - Principal Investigator
+39 0522 295467
vincenzodario.mandato@ausl.re.it
CONTACT